Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, discusses how LungTalk, a health communication and decision support tool, may spread awareness and knowledge surrounding lung cancer screening.
Closing out their discussion on the management of multiple myeloma, experts from the Moffit Cancer Center highlight key unmet needs and future directions in care.
Neil M. Iyengar, MD, highlighted the recent T-DXd and Dato-DXd approvals in breast cancer.
The expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.
Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.
A panelist discusses how tazemetostat offers a convenient, mutation-independent oral option for third-line follicular lymphoma treatment, balancing efficacy and tolerability while addressing patient lifestyle and financial considerations in an era of advanced therapies like CAR T-cell and bispecific antibodies.
Panelists discuss how effective management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in complex extensive-stage small cell lung cancer (ES-SCLC) cases treated with tarlatamab enables patients to continue therapy and achieve meaningful clinical benefit despite early toxicities.
At SGO 2022, Catherine Watson, MD, spoke about how to encourage patients with ovarian cancer to seek genetic testing.
Ghulam Gous, MD, and colleagues report a case of glioblastoma with extensive liver metastases along with a review of previous reports of liver metastasis from glioblastomas and the possible mechanisms of metastasis.
Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.
A lack of guidelines, a loss of follow-up, and out-of-state procedures are all potential reasons for 26% of patients undergoing appendectomy.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
An overview of what’s next, in terms of the use of various frontline treatment regimens, that include novel agents to manage patients with newly diagnosed multiple myeloma.
This video segment discusses strategies for patient education and preparation for second-line treatment with RAS GTPase inhibitors, as well as therapeutic options to consider if a patient progresses on adagrasib.
Panelists offer concluding perspectives on the future role of circulating tumor DNA in colorectal cancer management.